Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant diseaseM B Atkins, J A Gould, M Allegretta, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaG R Weiss, K A Margolin, M Sznol, et al.
Urologic Oncology|February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503Raman Jay, R R McKay, L Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Patient preferences for adjuvant interferon alfa-2b treatmentK L Kilbridge, J C Weeks, A J Sober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinomaJ S Du Bois, E G Trehu, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant diseaseM B Atkins, J A Gould, M Allegretta, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaG R Weiss, K A Margolin, M Sznol, et al.
Urologic Oncology|February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503Raman Jay, R R McKay, L Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Patient preferences for adjuvant interferon alfa-2b treatmentK L Kilbridge, J C Weeks, A J Sober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinomaJ S Du Bois, E G Trehu, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Pageof 11